Primary human tumor xenografted models (‘tumorgrafts’) for good management of patients with cancer
The DOI matches its Crossref record.
Abstract
The treatment of cancer is continually improving as a result of a better understanding of oncogenesis and the development of new targeted compounds. Early clinical trials evaluating such candidate compounds require a large number of patients, and are expensive, time consuming, and expose patients to certain risks. To select the most effective molecules, preclinical investigation of antitumor compounds is an important step in the drug development process. Three main categories of preclinical cancer models are generally used in preclinical investigations, namely genetically engineered models, xenografts derived from human tumor cell lines, and human tumor fragments from patients implanted directly into immunodeficient mice, known as tumorgrafts. The establishment of tumorgrafts constitutes a long-term process consisting of various steps, in which the final objective is to show that the validated model accurately reproduces human cancer, with a high predictive value of therapeutic efficacy (regardless of the type of treatment), and closely mimics clinical situations frequently observed in patients with cancer, such as resistance to standard treatments, metastases, and relapse after initial therapies (involving residual tumor-initiating cells). The aim of this study is therefore to discuss the proposed criteria for the establishment and validation of preclinical models of human cancers that should be used for further pharmacological assessments.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Unger, C., Kramer, N., Walzl, A., Scherzer, M., Hengstschläger, M., & Dolznig, H. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2014.10.015 · Cited by 158
Genetically Engineered Mouse Models: Closing the Gap between Preclinical Data and Trial Outcomes
Singh, M., Murriel, C. L., & Johnson, L. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2786 · Cited by 125
Kuo, C.-T., Liu, H.-K., Huang, G.-S., Chang, C.-H., Chen, C.-L., Chen, K.-C., Yun-Ju Huang, R., Lin, C.-H., Lee, H., Huang, C.-S., et al. (2014) · The Analyst · doi:10.1039/c4an00936c · Cited by 20
Metadata
- Authors
- Decaudin, D.
- Venue
- Anti-Cancer Drugs
- Published
- 2011-10
- Volume
- 22
- Issue
- 9
- Pages
- 827-841
- ISSN
- 0959-4973 (ISSN-L)
- OpenAlex
- W1966476566
- Cited by
- 49
- References
- 0
- FWCI
- 3.03
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Primary human tumor xenografted models (‘tumorgrafts’) for good management of patients with cancer. https://app.cochat.ai/papers/10.1097/cad.0b013e3283475f70
- The paper
- Decaudin, D. (2011). Primary human tumor xenografted models (‘tumorgrafts’) for good management of patients with cancer. Anti-Cancer Drugs. https://doi.org/10.1097/cad.0b013e3283475f70
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.